




The relative strengths and weaknesses of Diamedica Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Diamedica Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 136% points. The greatest weakness of Diamedica Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 365%, being 109% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	27,921
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,028
Liabilities, Non-Current	53
Other Assets	100
Other Compr. Net Income	-4.0
Other Expenses	27
Other Liabilities	0
Other Net Income	434
Other Revenues	0
Property and Equipment	74
Research and Development	8,310
Selling, General and Administrative Expense	4,389

Output Variable	Value in 1000 USD
Assets	28,095
Liabilities	2,081
Expenses	12,726
Revenues	0
Stockholders Equity	26,014
Net Income	-12,292
Comprehensive Net Income	-12,294
BaseVar	21,670
ECR before Limited Liability	294%
Economic Capital Ratio	365%